As of 2025-03-20, the EV/EBITDA ratio of Jounce Therapeutics Inc (JNCE) is 1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. JNCE's latest enterprise value is -51.62 mil USD. JNCE's TTM EBITDA according to its financial statements is -48.70 mil USD. Dividing these 2 quantities gives us the above JNCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 12.9x | 10.2x |
| Forward P/E multiples | 9.5x - 14.1x | 11.6x |
| Fair Price | (5.91) - (9.07) | (7.20) |
| Upside | -414.4% - -582.7% | -483.0% |
| Date | EV/EBITDA |